Back to Agenda
[V4-S6] Possibility of AI for Future New Drug Evaluation and Review Process
Session Chair(s)
Makoto Suzuki, PhD
Director, Medical Writing
MSD K.K., Japan
Share what next innovation technology is available in global drug development, such as AI translation in the medical field using multi-language speech translation technology of Ministry of Internal Affairs and Communications, and discuss shortening of approval review period using innovation such as AI.
Speaker(s)
High Quality Automatic Translation By Using AI
Eiichiro Sumita, PhD
National Institute of Information and Communications Technology (NICT), Japan
NICT Fellow, Associate Director General of ASTREC
Development and Influence of Digital Technonlogy
Kazuya Obanayama
Bayer Yakuhin, Ltd., Japan
Digital Transformation Product Leader & PMO, Commercial Operations Management
Creation of Package Inserts Post-Marketing Materials Using XML
Megumi Sato
MSD K.K., Japan
Sr, Specialist, Regulatory Operations
Have an account?